Publicaciones en colaboración con investigadores/as de Hospital Clinico Universitario de Valencia (21)

2008

  1. Langerhans cell histiocytosis

    Clinical and Translational Oncology, Vol. 10, Núm. 11, pp. 688-696

2004

  1. Effect of the methylenetetrahydrofolate reductase C677T polymorphism on patients with cisplatin/gemcitabine-treated stage IV non-small-cell lung cancer

    Clinical Lung Cancer, Vol. 5, Núm. 6, pp. 360-365

1996

  1. RESULTATS D'UNE ETUDE RANDOMISEE COMPARANT L'ASSOCIATION NAVELBINE®-CISPLATINUM A L'ASSOCIATION VINDESINE-CISPLATINUM ET A LA NAVELBINE® SEULE CHEZ 612 MALADES PORTEURS D'UN CARCINOME BRONCHIQUE NON A PETITES CELLULES INOPERABLE

    Bulletin du Cancer, Vol. 83, Núm. 5, pp. 385-394

  2. Value of CA 15.3 in breast cancer and comparison with CEA and TPA: A study of specificity in disease-free follow-up patients and sensitivity in patients at diagnosis of the first metastasis

    Breast Cancer Research and Treatment, Vol. 37, Núm. 3, pp. 209-216

1995

  1. Single agent Taxol, 3-hour infusion, in untreated advanced non-small-cell lung cancer

    Annals of Oncology

1994

  1. Phase II trial of cisplatin and etoposide as first-line therapy in metastatic breast carcinoma

    Oncology (Switzerland), Vol. 51, Núm. 4, pp. 352-355

  2. Quantitative monoclonal antibody determination of estrogen and progesterone receptors in human breast cancer: Correlation with the radioligand method

    Oncology (Switzerland), Vol. 51, Núm. 5, pp. 435-439

1993

  1. Epidermal growth factor in human breast cancer, endometrial carcinoma and lung cancer. Its relationship to epidermal growth factor receptor, estradiol receptor and tumor TNM

    Clinica Chimica Acta, Vol. 215, Núm. 1, pp. 51-63

1992

  1. DERRAMES NEOPLASICOS

    Revisiones en Cancer, Vol. 6, Núm. 3, pp. 104-109

1990

  1. Intratumoral variation of estrogen and progesterone receptors in breast cancer: Relationship with histopathological characteristics of the tumor

    Oncology (Switzerland), Vol. 47, Núm. 1, pp. 9-13

  2. Phase II study with high doses of epirubicin in patients with advanced rectal cancer

    Tumori, Vol. 76, Núm. 5, pp. 503-504

1989

  1. p29 Protein in breast cancer: Relation between estrogen and progesterone receptors

    Tumori, Vol. 75, Núm. 2, pp. 113-116

1988

  1. ALTERACIONES EN LAS PROBLACIONES Y SUBPOBLACIONES LINFOCITARIAS EN ADICTOS A DROGAS POR VIA PARENTERAL CON ANTICUERPOS FRENTE AL HIV

    Anales de Medicina Interna, Vol. 5, Núm. 2, pp. 61-65

  2. Protein C in malignancies. Influence of chemotherapy on protein C levels in patients with non nonsurgical lung neoplasms

    Sangre, Vol. 33, Núm. 5, pp. 347-351

  3. Study of toxicity and haemopoietic recovery induced by adjuvant chemotherapy in patients with breast neoplasms

    Sangre, Vol. 33, Núm. 3, pp. 171-177

1987

  1. Adjuvant chemotherapy with adriamycin, fluorouracil, cyclophosphamide, methotrexate, with or without tamoxifen in operable breast cancer

    Tumori, Vol. 73, Núm. 5, pp. 467-473

  2. Intratumoral variations in cytoplasmic estrogen receptor levels in breast cancer

    Breast Cancer Research and Treatment, Vol. 9, Núm. 1, pp. 69-70

1985

  1. INMUNODEFICIENCIA COMUN VARIABLE: HETEROGENEIDAD DE SUBPOBLACINES LINFOCITARIAS T DEFINIDAS POR ANTICUERPOS MONOCLONALES

    Anales de Medicina Interna, Vol. 2, Núm. 6, pp. 260-263

1984

  1. ACCION ANTIPLAQUETARIA DEL PIROZADIL

    Medicina Clinica, Vol. 82, Núm. 6, pp. 253-255

  2. QUIMIORRADIOTERAPIA CONVENCIONAL Y AGRESIVA DE LA LEUCEMIA GRANULOCITICA CRONICA EN SUS DIFERENTES FASES. OTROS PROBLEMAS TERAPEUTICOS

    Sangre, Vol. 29, Núm. 4 B, pp. 577-597